Novartis Pharmaceuticals Canada has partnered with Clarius Mobile Health to help improve access to ultrasound technology in the country for detecting psoriatic arthritis (PsA) in patients.
This will allow rheumatologists to identify diagnostic markers sooner.
Go deeper with GlobalData
As part of the agreement, the companies will provide access to handheld ultrasound devices for rheumatologists. It will also deliver training, support and education through in-person, virtual and asynchronous events.
Novartis will create evidence to assess and monitor adoption, usage and impact, and ways to use ultrasound in routine practice related to early PsA detection.
The Clarius L15 HD3 scanner is designed to automatically deliver clear and detailed ultrasound images of superficial anatomy.
The user-friendly scanner can wirelessly connect to an AI-powered app on the Apple and Android devices of clinicians.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataNovartis Canada country president Mark Vineis said: “At Novartis, we recognise the tremendous potential AI holds for our industry and the healthcare landscape at large.
“The partnership with Clarius has the potential to transform PsA detection, with the possibility of scaling to other Immunology indications, across specialities and beyond Canada.”
Psoriatic arthritis is said to be a chronic, autoimmune disease form of arthritis, which can cause joint inflammation such as swelling, pain and stiffness.
Clarius president and CEO Ohad Arazi said: “We are inspired by Novartis’ mission to improve care for PsA patients and their novel approach to help accelerate diagnosis with real-time ultrasound imaging.
“We believe that this type of partnership between a pharmaceutical and a medical technology company can play a tremendous role in improving patient outcomes and reducing the burden on our healthcare system.”
Earlier this year, Clarius Mobile Health obtained 510(k) clearance from the US Food and Drug Administration for its Clarius Bladder AI non-invasive tool to automatically measure bladder volume.
